Acrux Ltd (ASX:ACR) a specialty pharma company that develops and commercialises drugs.
Presenting Thu, 5:00 PM · John Warmbrunn, CEO
Presenting companies
Meet 55 Biotechs
Browse the full slate, save companies to your list, and request a 1:1 meeting at the conference or virtually after.
Presenting Thu, 12:20 PM · Steven Gourlay, CEO
"East to West" cellular immunotherapies and protein therapeutics for fatal diseases.
Not presenting
Not presenting
Amplia (ASX:ATX) has a highly promising drug in Phase 2 studies for solid tumours.
Presenting Thu, 12:35 PM · Chris Burns, CEO
Clinical-stage gene therapy medicines for neuromuscular diseases.
Not presenting
High-growth, profitable soft tissue regeneration company with US commercial operations.
Presenting Thu, 9:00 AM · Brian Ward, CEO · also Thu, 11:50 AM (James Agnew, CFO)
Clinical-stage CAR-iNKT company developing off-the-shelf cell therapies.
Not presenting
AI-powered coronary artery disease detection from a single CT scan.
Presenting Thu, 5:30 PM
Transforming the treatment of bipolar mania.
Not presenting
A blood test for earlier, more accurate breast cancer detection.
Presenting Thu, 3:00 PM
Presenting Thu, 2:30 PM · Henk-Jan Boele, CEO
CDH17 CAR-T for GI and neuroendocrine cancers. Reaching the unreachable.
Presenting Fri, 4:20 PM · Rebecca McQualter, CEO
Clarity is a clinical-stage radiopharmaceutical company developing cancer theranostics.
Presenting Thu, 10:10 AM · Alan Taylor, CEO
Cleo is developing a simple blood test for the early and accurate detection of ovarian cancer.
Presenting Thu, 3:10 PM · Dayna Louca, Head of Corp. Dev.
Commercial-stage AI-powered microbiology automation for pharma manufacturing.
Presenting Fri, 2:30 PM · Brent Barnes, CEO
Profitable global CNS tech leader enabling faster, higher-quality clinical trials.
Presenting Thu, 4:40 PM · Brad O'Connor, CEO
Late-stage therapies for kidney and inflammatory disease. DMX-200 in Phase 3.
Presenting Thu, 11:30 AM
Presenting Fri, 4:40 PM · Mary-Ann Rennie, CEO
Presenting Fri, 4:30 PM
Clinical stage, next generation cancer therapeutics for adult and paediatric patients.
Presenting Fri, 12:35 PM · Christian Toouli, CEO
HGX is a clinical-stage biotech developing precision therapies for multiple myeloma.
Presenting Fri, 11:00 AM · Chris Baldwin, CEO
A fungal chemistry platform displacing petrochemicals, starting in engineered wood.
Not presenting
Immuron is an enteric diseases platform company with commercial revenue and clinical-stage assets.
Not presenting
Developing next-generation multispecific biologic medicines for serious diseases.
Presenting Fri, 10:45 AM · Philippa Lewis, CEO
INOVIQ is pioneering exosome-based diagnostics and therapeutics that transform cancer care.
Presenting Thu, 2:40 PM · Leearne Hinch, CEO
Clinical-stage antivirals with expedited paths for Marburg, Ebola & dengue.
Presenting Fri, 3:35 PM · David Foster, CEO
Lateral Pharma is developing new drugs to treat and increase healthy longevity.
Presenting Thu, 5:15 PM · David Kenley, CEO
Clinical-stage biotech developing pathogen-agnostic AMR breakers.
Presenting Fri, 2:45 PM · Maud Eijkenboom, MD
Specialising in rapid, cost-effective and complete point-of-care diagnostic test solutions.
Presenting Fri, 3:05 PM
Specialty pharma advancing women's health and dermatology.
Presenting Thu, 9:50 AM · Aaron Gray, CEO
The Type 2 diabetes therapeutic market is globally $130 billion. Despite this, current therapies still fail to adequately address the core drivers of disease progression: inflammation, metabolic dysfunction, and loss of beta cell function.
Not presenting
Clinical-stage biotech developing proprietary psychedelic medicines for PTSD and MDD.
Not presenting
Neuren is developing new drug therapies to treat multiple serious neurological disorders.
Presenting Thu, 9:30 AM · Jon Pilcher, CEO
Neurizon Therapeutics (ASX: NUZ) is a late clinical-stage biotechnology company developing disease-modifying therapies designed to target impaired cellular protein clearance pathways associated with neurodegenerative diseases. Its lead investigational therapy, NUZ-001, is being evaluated in the Phase 2/3 HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis (ALS), with topline results expected in late Q2 2027, and is being developed with potential applicability across other neurodegenerative diseases. Neurizon combines differentiated science, clinical execution and commercial readiness to create long-term stakeholder value.
Not presenting
Not presenting
Maker of iTrack™ Advance, an implant-free minimally invasive glaucoma surgery device.
Not presenting
The global diagnostics company behind Cxbladder urine biomarker cancer tests.
Presenting Thu, 3:30 PM · Peter Meintjes, CEO
A clinical-stage therapeutic developer focused on a solution for attenuating delirium.
Presenting Fri, 11:40 AM · Samantha South, CEO
An immuno-oncology company with positive Phase I data from the US, about to start Phase II.
Not presenting
PLL Tx Australia is driving a new approach to MND diagnosis and therapy, targeting ALS.
Not presenting
ASX:PTX – clinical-stage oncology company developing PTX-100, a GGT-1ase inhibitor.
Not presenting
Earlier prediction. Informed decisions. Better outcomes.
Presenting Thu, 3:20 PM · David Morris, CEO
Clinical-stage biotech developing natural-source therapies for oncology and wound healing.
Not presenting
Racura Oncology is a Phase 3 stage clinical biopharmaceutical company on a mission to silence cancer.
Presenting Fri, 12:15 PM · Peter Smith, CEO
Presenting Fri, 3:20 PM · James Graham, CEO
Not presenting
Not presenting
An Australian innovative medical diagnostics company delivering simple, affordable blood tests for accurate, early detection of cancers.
Presenting Thu, 2:50 PM · David Atkins, CEO
Presenting Fri, 11:55 AM · Cheryl Maley, CEO
Presenting Thu, 12:05 PM · Gary Phillips, CEO
SYNthesis med chem, a global provider of integrated drug discovery & development services.
Not presenting
Commercial-stage radiopharmaceutical company advancing targeted cancer diagnostics and therapies.
Presenting Thu, 10:30 AM
First-in-class antifibrotic drug developer targeting pulmonary fibrosis.
Presenting Fri, 4:50 PM · Tara Speranza, CEO
Smart cryopreservation hardware and software preserving biomaterial quality (ASX:VFY).
Presenting Fri, 11:25 AM · Brent Owens, CEO